Article

Natural Food Additive Can Prevent Skin Cancer

Author(s):

Annatto is commonly found in the seeds of the achiote fruit.

A compound called bixin, found in the natural food additive annatto, can be used to help prevent skin cancer.

Annatto is commonly found in the seeds of the achiote fruit primarily used in Latin America as a cooking ingredient.

Bixin was found to work by preventing skin cells from forming and preventing ultraviolet radiation (UV)-triggered skin damage.

Prior studies had indicated that a gene expression — transcription factor called NRF2 – embodied protective mechanisms against sunlight. Georg Wondrak, PhD, the study’s lead author, wanted to explore if bixin was that compound that could activate the NRF2 network.

Wondrak conducted a study published in the journal Free Radical Biology and Medicine involving two groups of mice exposed to UV radiation — the first group was injected with bixin while the second group was left alone.

The study results showed that compared to the control group, those administered bixin injections yielded significantly less skin damage from the sun.

Experts highlighted that while bixin does not completely kill cancer cells, it does prevent the cancer from developing. The compound also makes the cells create protective antioxidants and repair factors.

The next step, Wondrak and Zhang, acknowledged, is to assess whether bixin can cause the same favorable results on humans.

As the FDA had dubbed annatto a safe food additive, the researchers anticipate more studies on the horizon to determine whether combining annatto with other food items could also protect the skin from sun damage, skin aging, and skin cancer.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards